Exhibit 99.1

Theragenics Corporation Reports Second Quarter 2013 Results

BUFORD, Ga.--(BUSINESS WIRE)--August 8, 2013--Theragenics Corporation

® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2013.

Consolidated Results

  • Revenue
    • $20.3 million in Q2 2013, down 8% from Q2 2012. $40.2 million in the first half of 2013, down 8% from 2012.
  • Earnings per share
    • $0.00 in Q2 2013 compared to $0.02 in Q2 2012 and $0.00 in the first half of 2013 compared to $0.05 in 2012.
    • Special items reduced EPS by $0.03 in both Q2 2013 and in the first half of 2013.
  • Operating income
    • $131,000 in Q2 2013 compared to $1.3 million in Q2 2012. $148,000 for the first half of 2013, compared to $2.9 million in 2012.
    • Excluding special items, operating income was $1.4 million in Q2 2013 and $1.5 million in the first half of 2013. See Table V.
  • Adjusted EBITDA
    • $2.5 million in Q2 2013 compared to $3.7 million in Q2 2012. $4.8 million in the first half of 2013 compared to $7.5 million in 2012.
    • Excluding special items, adjusted EBITDA was $3.7 million in Q2 2013 and $6.1 million in the first half of 2013. See Table IV.
  • Capital expenditures were $1.5 million in the first half of 2013.
  • The Medical Device Excise Tax, effective January 1, 2013, totaled $212,000 in Q2 and $405,000 in the first half of 2013.
  • At June 30, 2013, cash, cash equivalents and marketable securities were $37.2 million and credit facility borrowings were $22.0 million, resulting in a net positive position of $15.2 million.
  • In July 2013, we were notified by a customer that it would discontinue purchasing our wound closure products during the second half of this year. The loss of this customer is a result of increased pricing competition. Sales to this customer were $1.8 million in the first half of 2013.
  • Restructuring activities related to the closing of our Galt Medical facility in Texas continued, with an estimated completion date of December 2014.
    • The Galt Medical brand represents a growth platform business for us in which we intend to continue to invest and expand product offerings.
    • We incurred restructuring expenses and operational transition expenses related to the restructuring of $300,000 in the second quarter of 2013 and $393,000 in the first half of 2013.
    • We expect to incur incremental expenses totaling $3.7 million to $4.1 million (including expenses incurred through June 30, 2013) through 2014 to complete this restructuring. These incremental costs, expected to be recorded over the restructuring period through December 2014, primarily include severance related expenses and project implementation costs. No significant non-cash charges are expected to be recorded related to this restructuring.
    • Capital expenditures related to restructuring are expected to be $2.5 million to $2.7 million through 2014.
    • Upon completion of the restructuring, net cost reductions are expected to be $3.3 million to $3.6 million annually.

The following information was filed by Theragenics Corp (TGX) on Thursday, August 8, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Theragenics Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Theragenics Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account